About

Overview

We are a clinical-stage biopharmaceutical company developing new drugs for cardiovascular diseases.

Founded by cardiologists and backed by renowned Los Angeles hospital Cedars-Sinai, our aim is to make significant advances in the treatment of cardiovascular diseases by addressing mechanisms of inflammation that drive pathogenesis.  This has been a core area of research of our founding scientists for 30 years.

We develop biologic therapies for patients with significant unmet medical need.  Our pipeline focuses on treating atherosclerotic cardiovascular disease, inflammation, and cardiometabolic dysfunction in patients with psoriasis.  We also working to create therapies for patients at risk of cardiovascular complications from lipoprotein(a).  Neither condition has an approved therapy.

Our committed team of scientists and drug developers bring decades of therapeutics development experience and a track-record of success to the Company.

Management

kevin b bacon
Prediman K. Shah, M.D.
Jan Nilsson, M.D., PhD
Michael Hamill
Chris Farina, MS, RAC
Ryan Abbott, M.D., J.D.

Board of Directors

JOHN FARINA

Managing Director, Glenbarr Partners

WILLEM MESDAG

Managing Director, Red Mountain Capital

EDWARD M. PRUNCHUNAS

Chief Financial Officer, Cedars-Sinai Medical Center

PREDIMAN K. SHAH, M.D.

Director and Founder, Oppenheimer Atherosclerosis Research Center at Cedars-Sinai Medical Center

JAN NILSSON, M.D., PHD

Chairman, Clinical Research Center, Lund University

TIMOTHY WRIGHT, M.D.

General Partner, Time Bioventures

Strategic Advisers

D.A. WALLACH

KARAN BILIMORIA

Investors

Our Pipeline

Our pipeline focuses on patient populations at high-risk of cardiometabolic complications from underlying chronic inflammation.